ES2139553T1 - REPLICATION OF INFLUENZA VIRUSES IN A CULTIVATION OF MAMMALIAN CELLS AND VACCINE PRODUCTION. - Google Patents

REPLICATION OF INFLUENZA VIRUSES IN A CULTIVATION OF MAMMALIAN CELLS AND VACCINE PRODUCTION.

Info

Publication number
ES2139553T1
ES2139553T1 ES97921094T ES97921094T ES2139553T1 ES 2139553 T1 ES2139553 T1 ES 2139553T1 ES 97921094 T ES97921094 T ES 97921094T ES 97921094 T ES97921094 T ES 97921094T ES 2139553 T1 ES2139553 T1 ES 2139553T1
Authority
ES
Spain
Prior art keywords
replication
cultivation
mammalian cells
influenza viruses
vaccine production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES97921094T
Other languages
Spanish (es)
Inventor
Robert G Webster
Nicolai V Kaverin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Jude Childrens Research Hospital
Original Assignee
St Jude Childrens Research Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Jude Childrens Research Hospital filed Critical St Jude Childrens Research Hospital
Publication of ES2139553T1 publication Critical patent/ES2139553T1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA INVENCION PROPORCIONA LA REPLICACION DE LAS CEPAS DE MAS FUERTE CRECIMIENTO DEL VIRUS DE LA GRIPE, DERIVADAS DE AISLADOS CLINICOS, EN CELULAS CULTIVADAS DE MAMIFEROS, POR INFECCION DE LAS CELULAS DE MAMIFEROS CON LAS CEPAS DE FUERTE CRECIMIENTO, A FIN DE OBTENER CELULAS INFECTADAS, Y POR CULTIVO DE LAS CELULAS MIENTRAS SE MANTIENE EN EL MEDIO DE CULTIVO UN MARGEN DE CONCENTRACION DE TRIPSINA DE 0,05 A 1,0 MI G/ML, DONDE EL VIRUS REPLICADO RESULTANTE ES ADECUADO PARA SU USO EN VACUNAS CONTRA LA GRIPE DE LOS MAMIFEROS, ASI COMO PROCEDIMIENTOS DE VACUNACION QUE PROPORCIONA IGUALMENTE LA INVENCION.THE INVENTION PROVIDES THE REPLICATION OF THE STRONGEST STRAINS OF THE INFLUENZA OF THE FLU, DERIVED FROM CLINICAL ISOLATES, IN CULTIVATED CELLS OF MAMMALS, BY INFECTION OF THE CELLS OF MAMMALS, FINALLY GROWED, TO AND PER CULTURE OF THE CELLS WHILE A TRIPSINE CONCENTRATION MARGIN OF 0.05 TO 1.0 MY G / ML IS MAINTAINED IN THE CULTURE, WHERE THE RESULTING REPLICATED VIRUS IS SUITABLE FOR USE IN VACCINES AGAINST THE MAMMALS, AS WELL AS VACCINATION PROCEDURES ALSO PROVIDED BY THE INVENTION.

ES97921094T 1996-04-05 1997-04-02 REPLICATION OF INFLUENZA VIRUSES IN A CULTIVATION OF MAMMALIAN CELLS AND VACCINE PRODUCTION. Pending ES2139553T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62838496A 1996-04-05 1996-04-05
US08/664,783 US5824536A (en) 1994-08-23 1996-06-17 Influenza virus replicated in mammalian cell culture and vaccine production

Publications (1)

Publication Number Publication Date
ES2139553T1 true ES2139553T1 (en) 2000-02-16

Family

ID=27090697

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97921094T Pending ES2139553T1 (en) 1996-04-05 1997-04-02 REPLICATION OF INFLUENZA VIRUSES IN A CULTIVATION OF MAMMALIAN CELLS AND VACCINE PRODUCTION.

Country Status (8)

Country Link
US (2) US5824536A (en)
EP (1) EP0895535A4 (en)
AU (1) AU2722997A (en)
CA (1) CA2250716A1 (en)
DE (1) DE895535T1 (en)
ES (1) ES2139553T1 (en)
NO (1) NO984565L (en)
WO (1) WO1997038094A1 (en)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19612967A1 (en) * 1996-04-01 1997-10-02 Behringwerke Ag Process for the propagation of influenza viruses in cell culture, and the influenza viruses obtainable by the process
CA2355270A1 (en) * 1998-12-17 2000-06-22 Aventis Pasteur Limited Multivalent immunogenic composition containing rsv subunit composition and influenza virus preparation
IL136232A0 (en) * 2000-05-18 2001-05-20 Bar Ilan University Res Author Measurements of enzymatic activity in a single, individual cell in population
DE10144906B4 (en) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Process for the large-scale production of vaccines
EP2332651A3 (en) * 2001-10-25 2011-08-31 Bar Ilan University Interactive transparent individual cells biochip processor
US6830917B2 (en) 2001-12-10 2004-12-14 Baxter Healthcare S.A. Method of isolation and purification of trypsin from pronase protease and use thereof
US6951752B2 (en) * 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen
AU2002239151A1 (en) * 2002-03-08 2003-09-22 Crucell Holland B.V. Use of recombinant trypsin for vaccine production
US7465456B2 (en) * 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
CN1678345A (en) * 2002-04-26 2005-10-05 米迪缪尼疫苗股份有限公司 Multi plasmid system for the production of influenza virus
KR101251902B1 (en) 2003-02-25 2013-04-08 메디뮨 엘엘씨 Methods of producing inflenza vaccine compositions
US20060110406A1 (en) * 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
IL154677A0 (en) 2003-02-27 2003-09-17 Univ Bar Ilan A method and apparatus for manipulating an individual cell
WO2004110484A1 (en) * 2003-06-18 2004-12-23 Gosudarstvenny Nauchny Tsentr Virusologii I Biotekhnologii 'vektor' Method for producing a live tissue-cultural vaccine against influenza virus
JP4558652B2 (en) * 2003-06-20 2010-10-06 マイクロビクス・バイオシステムズ・インコーポレイテツド Improved virus production
US9200245B2 (en) 2003-06-26 2015-12-01 Seng Enterprises Ltd. Multiwell plate
US20060240548A1 (en) * 2003-06-26 2006-10-26 Mordechai Deutsch Materials for constructing cell-chips, cell-chip covers, cell-chips coats, processed cell-chips and uses thereof
US8597597B2 (en) * 2003-06-26 2013-12-03 Seng Enterprises Ltd. Picoliter well holding device and method of making the same
US7888110B2 (en) * 2003-06-26 2011-02-15 Seng Enterprises Ltd. Pico liter well holding device and method of making the same
WO2005008626A1 (en) * 2003-07-11 2005-01-27 University Of North Carolina At Chapel Hill Methods and systems for controlling a computer using a video image and for combining the video image with a computer desktop
US20050064524A1 (en) * 2003-08-11 2005-03-24 Mordechai Deutsch Population of cells utilizable for substance detection and methods and devices using same
US7037707B2 (en) * 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
AU2004308328B2 (en) * 2003-12-23 2009-06-04 Medimmune, Llc Multi plasmid system for the production of influenza virus
EP1711166A1 (en) * 2004-02-03 2006-10-18 Chemagis Ltd. Stable amorphous forms of montelukast sodium
US20080063251A1 (en) * 2004-07-07 2008-03-13 Mordechai Deutsch Method and Device for Identifying an Image of a Well in an Image of a Well-Bearing
US7403647B2 (en) * 2004-09-13 2008-07-22 Seng Enterprises Ltd. Method for identifying an image of a well in an image of a well-bearing component
WO2006021959A2 (en) * 2004-08-25 2006-03-02 Seng Enterprises Ltd. Method and device for isolating cells
DE602005024827D1 (en) * 2004-09-09 2010-12-30 Novartis Vaccines & Diagnostic REDUCTION OF POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINES
FR2878860A1 (en) * 2004-12-08 2006-06-09 Vivalis Sa HUMAN STEM CELL LINES DERIVED FROM ES CELLS AND USES FOR THE PRODUCTION OF RECOMBINANT VACCINES AND PROTEINS
AU2005322353B2 (en) 2004-12-23 2011-09-01 Medimmune, Llc Non-tumorigenic MDCK cell line for propagating viruses
EP1866075B1 (en) * 2005-01-25 2010-09-08 Seng Enterprises Limited Microfluidic device for studying cells
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
BRPI0612268A2 (en) * 2005-06-21 2009-01-27 Medimmune Vaccines Inc Isolated nucleic acid, expression vector, Methods for producing a genomic influenza rna, for producing a recombinant influenza virus, for generating a recombinant negative strand segmented rna virus in cultured canine cells, and for generating infectious influenza viral particles in cells cultivated canines, cell and virus
US7790434B2 (en) * 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
DE102005034043B4 (en) * 2005-07-18 2019-12-12 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Mixture containing L-carnitine and trehalulose and product containing the mixture
US20070111309A1 (en) * 2005-10-04 2007-05-17 Daelli Marcelo G Vero cell line adapted to grow in suspension
US20070141555A1 (en) * 2005-10-11 2007-06-21 Mordechai Deutsch Current damper for the study of cells
CN101365480B (en) * 2005-11-01 2014-11-05 诺华疫苗和诊断有限两合公司 Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment
US8288120B2 (en) * 2005-11-03 2012-10-16 Seng Enterprises Ltd. Method for studying floating, living cells
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
JP2009514844A (en) * 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル Emulsions containing free aqueous phase surfactants as adjuvants for split influenza vaccines
CA2628152C (en) 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
RU2457250C2 (en) 2006-04-19 2012-07-27 Медиммуне, Ллк Methods and compositions for expressing negative-sense viral rna in canine cells
EP3456348A1 (en) 2006-09-11 2019-03-20 Seqirus UK Limited Making influenza virus vaccines without using eggs
CN103361319A (en) 2006-09-15 2013-10-23 米迪缪尼有限公司 MDCK cell lines supporting viral growth to high titers and bioreactor process using the same
WO2008036285A1 (en) * 2006-09-18 2008-03-27 Energex Systems, Inc. Method of treating viral infections with ultraviolet light
EP1911836A1 (en) 2006-10-12 2008-04-16 AVIR Green Hills Biotechnology Trading GmbH Medium supplement for virus production
US20110053248A1 (en) * 2006-10-23 2011-03-03 Medimmune, Llc Serum-Free Virus Propagation Platform For A Virus Vaccine Candidate
CA2671629C (en) * 2006-12-06 2017-08-15 Novartis Ag Vaccines including antigen from four strains of influenza virus
UA100849C2 (en) * 2006-12-15 2013-02-11 Шеринг-Плау Лтд. Normal;heading 1;heading 2;heading 3;METHOD FOR REPLICATING INFLUENZA VIRUS IN CULTURE
AU2007334451A1 (en) * 2006-12-15 2008-06-26 Merck Sharp & Dohme (Holdings) Pty Ltd. Method for replicating influenza virus in culture
EP2139908A4 (en) * 2007-03-12 2011-02-16 Antigen Express Inc Li-rnai involved li suppression in cancer immunotherapy
US20080260774A1 (en) * 2007-04-13 2008-10-23 Chi-Huey Wong Alpha-galactosyl ceramide analogs and their use as immunotherapies
US7758867B2 (en) * 2007-06-15 2010-07-20 Biotrion Co., Ltd. Attenuated influenza virus and a live vaccine comprising the same
EP2674486A1 (en) 2007-06-18 2013-12-18 MedImmune, LLC Influenza B viruses having alterations in the hemaglutinin polypeptide
US9145540B1 (en) 2007-11-15 2015-09-29 Seng Enterprises Ltd. Device for the study of living cells
US9975118B2 (en) 2007-11-15 2018-05-22 Seng Enterprises Ltd. Device for the study of living cells
US7928077B2 (en) * 2008-07-11 2011-04-19 Academia Sinica Alpha-galactosyl ceramide analogs and their use as immunotherapies
JP5689796B2 (en) * 2008-08-01 2015-03-25 ガマ ワクチンズ ピーティワイ リミテッド Influenza vaccine
EP2334328A4 (en) 2008-09-24 2012-08-29 Medimmune Llc Methods for purification of viruses
CN103952376A (en) 2008-09-24 2014-07-30 米迪缪尼有限公司 Methods for cultivating cells, propagating and purifying viruses
PL2396032T3 (en) 2009-02-10 2017-05-31 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
JP2012525830A (en) * 2009-05-08 2012-10-25 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Method for producing virus from cell culture including homogenization
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
AU2010270722B2 (en) 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
EP2295543A1 (en) * 2009-09-11 2011-03-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the preparation of an influenza virus
US20110110975A1 (en) * 2009-11-06 2011-05-12 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
TW201202425A (en) 2010-04-28 2012-01-16 Abbott Biologicals Bv Production of viral components
US9426989B2 (en) * 2010-05-06 2016-08-30 Novartis Ag Organic peroxide compounds for microorganism inactivation
WO2012006367A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
BR112013018074A2 (en) 2011-01-13 2020-12-01 Variation Biotechnologies, Inc. methods for the preparation of vesicles and formulations produced from these
WO2012097346A1 (en) 2011-01-13 2012-07-19 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
EP2667891B1 (en) 2011-01-27 2021-10-06 Gamma Vaccines Pty Limited Combination vaccines
WO2012122625A1 (en) 2011-03-14 2012-09-20 National Research Council Of Canada Method of viral production in cells
US9956281B2 (en) 2011-05-04 2018-05-01 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
WO2013072768A2 (en) 2011-11-18 2013-05-23 Variation Biotechnologies, Inc. Synthetic derivatives of mpl and uses thereof
EP2802353A4 (en) 2012-01-12 2015-12-02 Variation Biotechnologies Inc Compositions and methods for treating viral infections
RU2698906C2 (en) 2012-01-27 2019-09-02 Вэриэйшн Биотекнолоджиз, Инк. Methods and compositions for therapeutic agents
EP3740234A1 (en) * 2018-01-18 2020-11-25 Yisheng Biopharma (Singapore) Pte. Ltd. Method for adapting influenza viruses to vero cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2445301A (en) * 1941-12-05 1948-07-13 Univ Pennsylvania Influenza vaccine
BE662899A (en) * 1964-04-22
US4500513A (en) * 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture
EP2290053A1 (en) * 1994-11-10 2011-03-02 Baxter Healthcare S.A. Method for producing Influenza virus in protein-free cell culture medium
AU694592B2 (en) * 1994-11-16 1998-07-23 St. Jude Children's Research Hospital Novel replication process

Also Published As

Publication number Publication date
AU2722997A (en) 1997-10-29
WO1997038094A1 (en) 1997-10-16
NO984565D0 (en) 1998-09-30
CA2250716A1 (en) 1997-10-16
EP0895535A4 (en) 2004-09-15
US6344354B1 (en) 2002-02-05
NO984565L (en) 1998-12-03
EP0895535A1 (en) 1999-02-10
DE895535T1 (en) 2000-03-02
US5824536A (en) 1998-10-20

Similar Documents

Publication Publication Date Title
ES2139553T1 (en) REPLICATION OF INFLUENZA VIRUSES IN A CULTIVATION OF MAMMALIAN CELLS AND VACCINE PRODUCTION.
EP2011862B1 (en) Method for manufacturing an active component of a medicine or diagnosis agent in MDCK cell suspension culture
ES2129386T1 (en) INFLUENZA VACCINE.
MX9306841A (en) UREASE BASED VACCINE AGAINST HELICOBACTER INFECTION IN MAMMALS.
Maassab et al. Laboratory and clinical characteristics of attenuated strains of influenza virus
BRPI0407636A (en) cell culture medium, animal cell lineage, methods for producing a conditioned culture medium, animal cells, an animal cell culture, virus in an animal cell culture, or preferably anchor-dependent diploid human, method for produce a vaccine, and virus population
US4188375A (en) Process for the preparation of vaccines
HK1019233A1 (en) Animal cells and processes for the replication of influenza viruses
EP1427817A1 (en) Multiplication of viruses in a cell culture
BR0212047A (en) Use of immunogen, polyamino or conjugate, immunogenic composition, nucleic acid fragment, vector, transformed cell, composition to induce amyloid antibody production, and stable cell line
CO5540349A2 (en) VACCINAL PREPARATION OF INACTIVATED INFLUENZA VIRUS
AR053286A2 (en) CULTIVATION OF CELLS FROM A CEPA DERIVED FROM A SPEC PROGENITRA OF A SPECIES OF NEOSPORA, VACCINE THAT CONTAINS THEM, METHODS TO PREPARE SUCH CULTURE, METHOD TO PREPARE A VACCINE WITH SUCH CULTURE, METHOD TO VACCINE A VACCINE THAT DATES CELLS
ES2042828T3 (en) VIRUS MODIFIED TUMOR VACCINE PREPARATION PROCEDURE FOR TUMOR METASTASIS IMMUNOTHERAPY.
ES2106784T3 (en) TRANSFER FACTOR AND METHODS OF USE.
PE72699A1 (en) ROTAVIRUS ANTIGEN, VACCINE AND DIAGNOSTIC AGENT FOR ROTAVIRUS INFECTION AND A METHOD TO PRODUCE THE ANTIGEN
AU1191188A (en) Influenza vaccine
ATE354370T1 (en) INACTIVATED IMMUNOGENIC BACTERIAL WHOLE CELL COMPOSITIONS
Fekadu et al. An immune stimulating complex (ISCOM) subunit rabies vaccine protects dogs and mice against street rabies challenge
CO4980849A1 (en) PHARMACEUTICAL COMPOSITIONS -2-HIDROXIMETIL-1,3-OXATIOLAN-5-IL) - (1H) -PIRIMIDIN-2-ONA (LA MIVUDINA), AND ITS USE IN MEDICAL THERAPY
HUP0101081A2 (en) Medium and method for viral propagation and growth
BR0102322A (en) Virus from an infectious bursal disease virus strain, vaccine against infectious bursal disease, methods for preparing the virus, and the vaccine, and using the virus
BR0307512A (en) Methods for producing a continuous cell line, for generating and / or isolating and / or maintaining a marek disease virus strain, for producing a diagnostic antigen for a marek disease virus, for preparing a vaccine capable of inducing protection against disease in a vertebrate, and to protect a vertebrate against disease, a cell or its offspring, cell preparation, use of it, vaccine, and use of it
ES2085888T3 (en) VACCINE COMPOSITION.
Churchill Intranuclear inclusions produced by bovine para-influenza
DK1430109T3 (en) Cultivation of mycobacteria